ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0678

Is There a Difference in Self-reported Flare Frequency Between Men and Women?

Naomi Schlesinger1, Nicholas A Sumpter2, Nicola Dalbeth3, Lisa Stamp4 and Tony Merriman5, 1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2University of Otago, Dunedin, New Zealand, 3University of Auckland, Auckland, New Zealand, 4University of Otago, Christchurch, Christchurch, New Zealand, 5University of Alabama at Birmingham, Dunedin, New Zealand

Meeting: ACR Convergence 2021

Keywords: gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I (0660–0682)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: There is increasing recognition of gout among women. The postmenopausal rise in serum urate levels in women increases the risk for the development of gout. Compared with men with gout, women with gout are older and had a more significant burden of comorbid conditions, including hypertension, diabetes, chronic kidney disease, obesity, and diuretic use (1). The risk of flares is associated with older age and cardiometabolic comorbidities. Female gout patients with cardiometabolic comorbidities were 60% more likely to have flared as compared with 10% in men (2,3). The profiles of women and men with gout are markedly different. Do women, especially women older than 65, have more frequent gout flares than men?

Methods: Using three cohorts of European gout patients from New Zealand (NZ European; 715 male, 147 female), USA (Ardea; 1,121 male, 57 female), and several European countries (GlobalGout; 726 male, 83 female) respectively, we analyzed sex differences between the number of self-reported flares in the last 12 months. We also filtered for individuals older than three age thresholds: > 65, > 75, and > 85 years old. Since there was significant skew in the flare data, we performed a non-parametric Wilcoxon rank-sum test in each cohort to statistically test for a difference in the mean number of flares between males and females. Bonferroni corrected P-value of 0.017 (0.05 / 3) was used for significance testing.

Results: There was a non-significant difference in flare rate between males and females within each cohort (Ardea p = 0.11, GlobalGout p = 0.51, NZ European p = 0.055). Figure 1 shows the distribution of flares in the past 12 months among males and females in each cohort, demonstrating the non-significant difference in flare rate between malesand females within each cohort. In addition, no significant difference in flare rate between sexes when filtering for individuals older than either of three age thresholds: > 70 years old: 401 male, 125 female – p-value = 0.76; > 75 years old: 188 male, 76 female – p-value = 0.61.

Conclusion: In this large cohort of gout patients, we found the rate of self- -reported gout flares in women similar to those of men.

References
1. Lally et al. Arch Intern Med. 1986;146:2221–2225.
2. Harrold et al. BMC Musculoskelet Disord. 2017 14;18:108.
3. Primatesta et al. BMC Musculoskelet Disord 2011;12:103.

Figure 1: Violin plots showing distribution of self-reported flares in the past 12 months among males and females in three European gout cohorts.


Disclosures: N. Schlesinger, Horizon, 2, Novartis, 2, Alnylam, 2, Pfizer, 5, AMGEN, 5; N. Sumpter, None; N. Dalbeth, AstraZeneca, 2, JW Pharmaceutical Corporation, 2, PK Med, 2, Horizon, 2, Selecta, 2, Dyve Biosciences, 2, Arthrosi, 2, Amgen, 5; L. Stamp, None; T. Merriman, None.

To cite this abstract in AMA style:

Schlesinger N, Sumpter N, Dalbeth N, Stamp L, Merriman T. Is There a Difference in Self-reported Flare Frequency Between Men and Women? [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/is-there-a-difference-in-self-reported-flare-frequency-between-men-and-women/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-there-a-difference-in-self-reported-flare-frequency-between-men-and-women/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology